Zinacef

Selected form

Cefuroxime

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal, Bactericidal Broad Spectrum

Treatment option: Abscess, Bacterial Pneumonia, Bronchitis, Bronchiectasis, Community Acquired Pneumonia, Gonorrhea, Infection, Infection,Urinary Tract, Meningitis, COPD,Acute

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zinacef

What is Zinacef? (Cefuroxime)

Property	Description
Active ingredient	Cefuroxime
Form	Powder for injection, Tablet, Oral suspension
Pharmacological Class	Second-generation Cephalosporin (Antibiotic)
General Purpose	Systemic antibacterial treatment
Origin	Semi-synthetic compound

What Kind of Medicine is Zinacef (Cefuroxime)?

Zinacef is a prescription-only medicine whose active ingredient is Cefuroxime, placing it within the family of beta-lactam antibiotics and specifically classifying it as a second-generation cephalosporin. This classification defines Cefuroxime as a potent systemic anti-infective agent used to combat the proliferation of harmful bacteria throughout the body. The compound is a semi-synthetic derivative, meaning it is chemically modified from naturally occurring substances to enhance its stability and effectiveness.

Cefuroxime is associated with broad-spectrum activity against various susceptible bacteria. This effectiveness is clinically recognized for its ability to target microorganisms that cause common systemic bacterial infections in both adults and pediatric patients.

The Composition and Purpose of a Second-Generation Cephalosporin

The Cefuroxime active ingredient is prepared in different chemical forms to accommodate various routes of administration, a key feature of this INN. For immediate delivery, such as intravenously or intramuscularly, it is used as Cefuroxime sodium (in a powder form). Conversely, when taken by mouth as a tablet or oral suspension, the medicine is a compound called Cefuroxime axetil, which acts as an orally absorbed prodrug that the body converts into the active Cefuroxime substance.

The primary function of this single-substance product is to provide bactericidal action, meaning it directly kills the target bacteria, rather than merely halting their growth. This general purpose confirms its use as a decisive defense tool in antibacterial treatment, often used as a standard choice when a broad-spectrum, bacteria-killing compound is required for the elimination of systemic bacterial infections.

What side effects are possible with Zinacef?

Possible Side Effects and Safety Information

The safety profile of Cefuroxime (Zinacef) is formally documented in regulatory texts, categorizing potential adverse reactions by frequency and physiological system (System-Organ Class or SOC).

Frequency-Classified Adverse Reactions

The official labeling organizes potential effects using standard frequency terminology, such as Common (affecting up to 1 in 10 patients) or Uncommon (affecting up to 1 in 100 patients).

Classification	Examples of Documented Effects
Common	Overgrowth of Candida, eosinophilia, headache, dizziness, and gastrointestinal disturbances (diarrhoea, nausea, vomiting, abdominal pain).
Uncommon	Leukopenia, thrombocytopenia, rash, pruritus (itching), and a positive Coombs test.
Not Known	Anaphylaxis, angioedema, haemolytic anaemia, and seizures.

Serious Adverse Reactions and Safety Notes

The most serious documented effects include severe hypersensitivity reactions like anaphylaxis and severe skin conditions (e.g., Stevens-Johnson syndrome). The medicine is also associated with Clostridioides difficile-associated diarrhoea (CDAD) and, rarely, kidney inflammation (acute interstitial nephritis).

Safety restrictions indicate the medicine is contraindicated in individuals with a known allergy to cephalosporins or a history of severe hypersensitivity to any other beta-lactam antibiotic. The official safety data also notes that the transient rise in liver enzymes and the positive Coombs test are observations more commonly seen at the beginning of treatment and are generally reversible. Caution is advised in patients with renal or severe hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation describes the overdose profile for Zinacef (Cefuroxime) based on specific neurological risks and required emergency responses.

Documented Overdose Manifestations and Risks

Acute overdosage is primarily associated with Central Nervous System (CNS) effects. The principal documented manifestation is cerebral irritation, which may lead to severe neurological outcomes, including convulsions or seizures. The risk of drug toxicity is formally noted to be elevated in patients with impaired renal function due to slower excretion, which can result in increased systemic concentrations.

Mandated Immediate Actions

Regulatory guidance mandates that immediate medical attention be sought for any suspected overdose, even if no symptoms are apparent. Patients must call emergency services immediately if the affected person has collapsed, is experiencing a seizure, has trouble breathing, or cannot be awakened. Contacting a Poison Control Center is also required for immediate, specialized guidance.

Official Management and Procedures

Management of Cefuroxime overdosage is described as symptomatic and supportive treatment. No specific antidote is known or listed in the regulatory prescribing information. Procedures for drug removal are specified, noting that high serum concentrations of Cefuroxime can be reduced effectively through hemodialysis or peritoneal dialysis.

Therapeutic Uses of Zinacef

What Zinacef Treats: Main Uses and Benefits

As a second-generation cephalosporin, Zinacef (Cefuroxime) is used to help with eliminating susceptible bacterial pathogens, contributing to easing the overall symptom load caused by the illness. It exhibits broad-spectrum activity, making it applicable within clinical settings that involve acute bacterial infections.

This medication is commonly used to help with managing infections that cause pronounced symptoms, including pneumonia, acute bacterial exacerbations of bronchitis, septicemia, and meningitis. It also is considered relevant for managing localized conditions like acute bacterial sinusitis, uncomplicated urinary tract infections (UTIs), acute otitis media (ear infection), and the symptoms of early Lyme disease. By targeting the bacterial cause, the treatment provides support that helps ease the overall symptom burden of high fever, pain, and acute localized discomfort.

“The goal of Cefuroxime use is to provide supportive anti-infective relief, assisting with maintaining functional stability during periods of heightened symptoms.”

Therapeutic Role: Relief for Acute Discomfort

Symptomatic Context	Therapeutic Benefit
Respiratory Distress	Contributes to easing symptoms that create noticeable physiological strain, such as severe cough and purulent sputum production.
Systemic Inflammation	Contributes to improved comfort during periods of heightened symptoms, such as high fever and chills.
Surgical Prevention	Applied to address heightened physiological stress and support patients during difficult episodes, such as postoperative complications.

Regulatory References

Cefuroxime - StatPearls - NCBI - NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Zinacef (Cefuroxime)?

Official regulatory documents define eligibility for Zinacef based on hypersensitivity history, age, and organ function, establishing specific population restrictions and contraindications.

Contraindicated Populations

Use is contraindicated and must be avoided in patients with a history of severe allergic reactions (hypersensitivity) to:

Cefuroxime itself or any formulation components.
Any other cephalosporin antibiotic.
Any other beta-lactam antibacterial agent, such as penicillins or carbapenems.

Eligibility by Age and Organ Function

Population Group	Eligibility Status
Adults and Adolescents	General use is established (typically 13 years and older).
Infants (< 3 Months)	Oral formulation use is not established (IV/IM use documented from birth).
Renal Impairment	Restricted use is necessary; patients with markedly impaired renal function often require a reduced dose.
Pregnancy/Lactation	Use during pregnancy is permitted only if clearly needed; use during lactation is generally acceptable.

Use of Zinacef requires caution in patients with a history of colitis or gastrointestinal disease and those receiving concurrent potent diuretics.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Zinacef (Cefuroxime) primarily involve alterations in drug exposure and additive pharmacodynamic effects, as documented in regulatory information.

Pharmacokinetic Interactions

Interacting Substance	Resulting Effect
Probenecid	Significantly increases Cefuroxime systemic levels by reducing renal clearance. Co-administration is generally not recommended.
Acid-Reducing Drugs (Antacids, H2-Antagonists, PPIs)	Decrease the bioavailability and absorption of oral Cefuroxime axetil.

To manage reduced absorption, regulatory guidelines recommend administering oral Cefuroxime at least 1 hour before or 2 hours after antacids.

Pharmacodynamic and Other Interactions

Interacting Substance/Class	Clinical Constraint/Note
Potent Diuretics or Aminoglycosides	Use with caution due to the documented potential for additive nephrotoxicity (kidney damage).
Anticoagulants (e.g., Warfarin)	Requires monitoring of Prothrombin Time/INR due to the potential for prolonged clotting time.
Oral Contraceptives	May reduce the efficacy of combined estrogen/progesterone contraceptives by affecting gut flora.

Interference with Laboratory Tests

Cefuroxime may cause non-glucose-based false-positive results in copper reduction tests for urine glucose (e.g., Benedict's, Fehling's, Clinitest) and may cause a positive Coombs test, which can interfere with blood cross-matching procedures.

Mechanism of Action

Cefuroxime is a beta-lactam compound that chemically mediates an inhibitory effect on bacterial viability through two primary mechanistic domains within susceptible organisms.

Inhibiting Bacterial Cell Wall Synthesis

Cefuroxime chemically engages enzyme-mediated signaling, specifically targeting Penicillin-Binding Proteins (PBPs) within the bacterial periplasmic space. By binding covalently to these enzymes, the compound modifies early molecular steps by blocking the transpeptidation process required for the cross-linking of the peptidoglycan layer, which is crucial for cell wall structural integrity. This initiates signaling sequences that lead to downstream effects like the activation of autolytic enzymes. The resulting physiological effect is the weakening of the bacterial cell wall, culminating in cellular osmotic instability and structural breakdown (lysis).

Maintaining Functional Integrity via beta-Lactamase Stability

The compound demonstrates stability against the hydrolytic activity of certain bacterial beta-lactamase enzymes. beta-Lactamases are bacterial enzymes that typically cleave and inactivate beta-lactam molecules. This inherent stability against some cephalosporinases and penicillinases allows the molecule to maintain its structural integrity and functional capacity, preserving the compound's concentration and function against certain strains.

Dosage and Administration Information

How to Use Zinacef (Cefuroxime)

Zinacef is administered using specific methods and schedules established for this medication. The medication comes in two distinct forms: Cefuroxime sodium is prepared for Intravenous (IV) or Intramuscular (IM) injection, while the orally administered prodrug, Cefuroxime axetil, is available as tablets or an oral suspension.

Standard Administration Patterns

Administration Route	Standard Frequency	Administration Condition
Oral Tablets	Typically twice daily (q12h)	Swallowed whole; without regard to food
Oral Suspension	Typically twice daily (q12h)	Must be taken with food for optimal absorption
IV/IM Injection	Two to four times daily	IV bolus over 3–5 minutes or infusion over 30–60 minutes

Dosing and Duration

Standard oral dosing for adults ranges from 250 mg to 500 mg per dose. For parenteral use in severe infections, doses of up to 1.5 g may be administered every 8 hours. The duration of therapy generally lasts between 5 and 10 days, though specific conditions like early Lyme disease require a longer course of 14 to 21 days. A common protocol for severe cases is sequential therapy, where the initial treatment is given parenterally for 48 to 72 hours before transitioning to the oral form to complete the course.

Population Adjustments

Standard clinical protocols involve the dosing frequency being reduced in patients with impaired renal function, based on their measured creatinine clearance. For pediatric patients, dosing is based on a weight-based calculation (mg/kg/day).

Recent Clinical Evidence

Research Evidence for Zinacef (Cefuroxime)

The body of research for the medicine Cefuroxime (Zinacef) primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews, which are study designs used to compare the effects of one treatment against another or against a placebo. This overview summarizes what types of research have been conducted, what outcomes were measured, and where evidence limitations exist, according to authoritative sources.

Evidence for Acute Bacterial Infections in the Lungs and Airways

Research exploring the use of Cefuroxime for conditions like pneumonia and acute exacerbations of bronchitis includes numerous short-term clinical evaluation trials. These studies focused on adult and older pediatric populations. Researchers primarily monitored outcomes related to physical discomfort and systemic imbalance, such as the rates of clinical success (the resolution or improvement of symptoms like fever and cough) and the rates at which the target bacteria were eliminated from the system. Findings describe patterns observed in the studies related to measured changes in symptoms and how they were monitored against other anti-infective agents.

Evidence for Use in Early Lyme Disease

Cefuroxime was studied for managing early Lyme disease, which is a condition often recognized by the distinctive skin rash known as Erythema Migrans. The evidence base includes comparative clinical trials that explored the use of Cefuroxime in managing early Lyme disease alongside other treatment options. These studies monitored outcomes related to the resolution of the rash and whether later, more complicated symptoms were observed.

Evidence for Surgical Infection Prevention (Prophylaxis)

The use of Cefuroxime in research contexts evaluating the prevention of infections that may arise after surgery (surgical prophylaxis) was monitored in numerous large-scale randomized clinical trials and meta-analyses. Researchers monitored the primary outcome, which was the incidence of Surgical Site Infection (SSI), as well as outcomes reflecting the rate of postoperative complications. Follow-up durations were limited in most of this research, which means there is limited information for long-term outcomes regarding the prevention of infections beyond the standard 30-day post-operative monitoring period.

Key Uncertainties and Research Gaps

The available evidence base highlights several key areas of uncertainty and limitation: The long-term effects are not fully established across most indications. For specific populations, such as very young infants or individuals with complex, pre-existing health issues, evidence is limited. Finally, a significant portion of the foundational comparative evidence is lacking against the most recently approved anti-infective agents recommended in some clinical guidelines today.

Key Studies & References

NIH StatPearls: Cefuroxime

Frequently Asked Questions (FAQ)

Common questions about Zinacef (FAQ)

Q: What is the main purpose of Zinacef and what infections is it used for?

Zinacef is a systemic antibacterial agent. Official product information states it is used to treat a variety of bacterial infections, including uncomplicated urinary tract infections (UTIs), acute otitis media (middle ear infection), and uncomplicated skin and soft tissue infections.

Q: Is Zinacef the same kind of antibiotic as penicillin?

No, Zinacef belongs to the cephalosporin class, while penicillin is in the penicillin class. Both are beta-lactam antibiotics. Regulatory documents state that patients with a history of severe allergy to penicillin should be assessed for potential cross-sensitivity, as Zinacef is related to penicillins.

Q: Is Zinacef safe and effective for use in infants and children?

The official product information establishes the use of Zinacef for pediatric patients (children) aged 13 and older for certain infections. For the oral suspension, there is no experience of using it in children under the age of 3 months, but use is indicated in children from the age of 3 months with weight-based dosing.

Q: Are there different forms of Zinacef (tablets vs. suspension) and do they work the same way?

The tablets and oral suspension are not bioequivalent, meaning the body absorbs and uses them differently. Regulatory documents state they should not be substituted for one another on a milligram-per-milligram basis. These two formulations were studied in separate clinical trials, which established their difference in absorption.

Q: Can Zinacef tablets be crushed or broken if a person has trouble swallowing?

Regulatory information advises that the tablets should be swallowed whole, and not crushed or chewed. This is because the crushed tablet has a strong, bitter taste.

Q: Can Zinacef cause drowsiness or make a person feel sleepy?

Yes, regulatory documents list dizziness and drowsiness as potential side effects, especially when higher doses are used. This side effect is noted as a possibility, and official information advises caution regarding activities requiring mental alertness.

Q: Is it possible for bacteria to become resistant to Zinacef after repeated use?

Yes. According to official warnings, the misuse or overuse of any antibacterial drug, including Zinacef, could lead to the development of drug-resistant bacteria and limit the drug's future effectiveness. Regulatory warnings state that using the medication exactly as prescribed is important for maintaining its effectiveness.

Q: Why are antacids said to interfere with the absorption of Zinacef?

Regulatory data indicates that antacids and other acid-reducing medications can reduce the body's absorption of the oral form of Cefuroxime (Zinacef). The reason for this is a pH-dependent reduction in drug dissolution; the medication requires a certain acidic level to dissolve correctly.

Q: Has Zinacef been studied for use in specific bacterial infections like pneumonia or UTIs?

Yes, official indications for Zinacef include the treatment of uncomplicated urinary tract infections (UTIs) caused by susceptible organisms. It is also studied and indicated for lung and airway infections, such as acute bacterial exacerbations of chronic bronchitis.

Q: Can Zinacef be used for infections like strep throat or tonsillitis?

Yes, official therapeutic indications confirm that Zinacef is used for the treatment of acute streptococcal tonsillitis and pharyngitis (often referred to as strep throat) in adults and children over 3 months of age.

Q: How long does it typically take to start feeling better after beginning treatment with Zinacef?

The official product information does not specify a timeline for when a person may feel clinical improvement, as this can vary. However, official information on pharmacokinetics indicates the medication reaches its highest concentration in the bloodstream approximately 2 to 3 hours after a dose of the tablet formulation is taken.

Q: How long do common side effects from Zinacef usually last?

Official safety data for certain effects, such as the transient rise in liver enzymes and a positive Coombs test, notes they are generally reversible. The duration of other common effects is not generally specified in regulatory documents.

Q: Does Zinacef have a known or common unpleasant taste?

Yes. Official patient information notes that the tablet form, if crushed or broken, has a strong bitter taste. This is consistent with the regulatory instruction to swallow the tablet whole.

Q: Are there any known interactions between Zinacef and alcohol consumption?

Yes. Patient safety information advises that alcohol can increase the risk of CNS side effects such as dizziness or drowsiness. Official patient information recommends limiting alcoholic beverages during treatment.

Q: Are there any specific safety concerns for older adults (geriatric patients) taking Zinacef?

Regulatory information indicates that dosage adjustment is generally not necessary based on age alone. However, older patients are more likely to have reduced renal function (kidney function), which may require a dosage adjustment.

Q: What kind of bacteria (e.g., Gram-positive or Gram-negative) is Zinacef active against?

Zinacef is classified as a broad-spectrum antibiotic. Official microbiology data indicates that it has demonstrated activity against a wide range of susceptible bacteria, including both Gram-positive and Gram-negative strains.

Q: What is the importance of completing the full course of Zinacef, even if symptoms improve quickly?

Regulatory warnings emphasize the importance of taking the full prescribed course exactly as directed. This is necessary to ensure the elimination of the infection and to help reduce the development of drug-resistant bacteria.

Q: What should I do if I forget or miss a dose of Zinacef?

This specific instruction for managing a missed dose is detailed in the How to Use Zinacef section of the full product information. The regulatory guidance provides specific timeframes for what to do when a dose is forgotten.

Q: Is there any research that discusses the effectiveness of Zinacef for skin infections?

Yes. The official label includes uncomplicated skin and soft tissue infections as a formal therapeutic indication for which Cefuroxime is used.

Q: Does Zinacef interfere with the effectiveness of certain 'live' vaccines?

Yes. According to patient information, this medication may cause certain live bacterial vaccines (such as the oral typhoid vaccine) to be less effective. Patients are advised to share a full medical history, including vaccination status, with their healthcare provider.

Q: What does the research say about Zinacef's use in cases of severe illness like meningitis?

Official regulatory documents confirm that the injectable form of Cefuroxime is indicated for the treatment of meningitis caused by susceptible organisms in some patient populations. This use is typically associated with the injectable form of the medication.

Q: Can Zinacef be used to treat infections in the ear, nose, and throat (ENT)?

Yes, Zinacef is indicated for treating a number of infections in the ear, nose, and throat area. These include acute otitis media, acute tonsillitis and pharyngitis, and acute bacterial sinusitis.

Q: Are there any known side effects related to the injection form of Zinacef?

Yes, official safety data lists documented adverse reactions specifically related to the injection site. These include pain and thrombophlebitis (inflammation of the vein) at the site of administration.

Q: Is there evidence regarding the use of Zinacef for the treatment of gonorrhea?

Yes. Official indications for Cefuroxime list the treatment of uncomplicated gonorrhea caused by susceptible strains of Neisseria gonorrhoeae.

Q: Can taking Zinacef cause a person to feel unusually tired or experience malaise?

Official patient safety information advises that unusual tiredness or weakness may occur. The regulatory information indicates that patients should report these symptoms to a healthcare professional for assessment.

Q: What should be done if stomach pain or cramps occur after taking Zinacef?

If prolonged or significant diarrhea or abdominal cramps occur, official warnings state this could be a sign of a more serious condition, such as Clostridioides difficile-associated diarrhea (CDAD). Patients are advised to contact a healthcare professional immediately for evaluation.

How should Zinacef be stored and disposed of?

Storage and Disposal of Zinacef

The storage of Zinacef (cefuroxime for injection) is strictly defined by regulatory guidelines based on the product state.

Labeled Storage Conditions

Product Form	Temperature Range	Protection Requirement
Unreconstituted Powder	Controlled room temperature (20 C to 25 C)	Store in original carton to protect from light.
Reconstituted Solution	2 C to 8 C (refrigerated)	Stable for up to 7 days at this temperature.

Handling and Disposal Rules

Reconstituted solutions stored at room temperature are stable for 24 hours. Solutions that have been frozen and thawed must not be refrozen. The product must be stored out of the sight and reach of children.

Disposal of any unused or expired Zinacef must not be done via wastewater or household trash. The medicine must be discarded according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.